Roth Capital Raises Uroplasty to Buy (UPI)

By admin | 6 years ago

Uroplasty (NYSE: UPI) was upgraded by Roth Capital from a “neutral” rating to a “buy” rating in a research note issued on Tuesday.

UPI has been the subject of a number of other recent research reports. Analysts at Dougherty & Co cut their price target on shares of Uroplasty from $6.50 to $5.00 in a research note to investors on Friday, March 30th. They now have a “buy” rating on the stock. Separately, analysts at Craig Hallum initiated coverage on shares of Uroplasty in a research note to investors on Tuesday, March 27th. They set a “buy” rating on the stock. Finally, analysts at McNicoll Lewis & Vlak initiated coverage on shares of Uroplasty in a research note to investors on Thursday, March 1st. They set a “buy” rating on the stock.

Uroplasty remained flat at $3.23 during trading on Tuesday. The company’s market cap is $66.9 million.

Uroplasty, Inc. is a medical device company that develops, manufactures and markets products for the treatment of voiding dysfunctions.

About the author